Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women With Post-traumatic Stress Disorder
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Verucerfont (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 31 Mar 2015 Trial design presented at the Trials.
- 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.